AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21789429
Drug: 0.8 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg/day of soy protein
Trial: 21789429
Drug: 0.8 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg/day of soy protein plus fibers
Trial: 21789429
Drug: 0.8 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg/day of animal protein
Trial: 11437696
Drug: Newer 5-ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer 5-ASA formulations
Trial: 11437696
Drug: 5-ASA-containing preparations
RxNorm normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA-containing preparations
Trial: 9678070
Drug: 0.28 mg
RxNorm normalized name: amitraz 0.28 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.28 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Trial: 9678070
Drug: 0.32 mg
RxNorm normalized name: gonadorelin 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.32 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Trial: 9678070
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (0.28 mg and 0.32 mg ethinylestradiol)
Trial: 8026301
Drug: Ethanol 1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 1.00 g/kg
Trial: 2530317
Drug: Intravenous floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous floxuridine (IV FUDR)
Trial: 29049935
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (IN-OT) 36 IU daily for 4-6 weeks
Trial: 23563576
Drug: LCZ696 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 200 mg b.i.d.
Trial: 23563576
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg b.i.d.
Trial: 22825654
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) administered orally prior to FDG-PET in 65 patients
Trial: 19936917
Drug: UFT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (oral tegafur-uracil) for 2 years
Trial: 15956984
Drug: Amoxapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxapine (up to 250 mg/day)
Trial: 15956984
Drug: Risperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (up to 5 mg/day)
Trial: 12385688
Drug: pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam 200 mg tid for 7 days
Trial: 12385688
Drug: pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam 200 mg bid for 7 days
Trial: 12385688
Drug: pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pivmecillinam 400 mg bid for 3 days
Trial: 12385688
Drug: norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin 400 mg bid for 3 days
Trial: 10447316
Drug: Interferon-alpha treatment
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha treatment for at least 24 weeks
Trial: 10447316
Drug: Negative qualitative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative qualitative HCV RNA test after 12 weeks of interferon treatment
Trial: 10447316
Drug: Prolonged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged treatment with interferon-alpha (> 6 months)
Trial: 7839429
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose arginine vasopressin (AVP) infusion, n = 11
Trial: 7839429
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose arginine vasopressin (AVP) infusion
Trial: 2201722
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg with ethanol (0.2‐0.4 g/kg)
Trial: 2201722
Drug: Nitrazepam 5
RxNorm normalized name: nitrazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 5 mg with ethanol (0.2‐0.4 g/kg)
Trial: 2201722
Drug: Ethanol alone
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol alone (0.2‐0.4 g/kg)
Trial: 2201722
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg and Nitrazepam 5 mg with ethanol
Trial: 28283596
Drug: IncobotulinumtoxinA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (all doses)
Trial: 28823623
Drug: J-Tip Needleless
RxNorm normalized name: hydroxypropyl cellulose (type J)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J-Tip Needleless Injection System®
Trial: 25929699
Drug: Appropriate shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate shock therapy in women
Trial: 25929699
Drug: Appropriate shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate shock therapy in men
Trial: 23761424
Drug: Antagonist coactivation
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist coactivation percentage
Trial: 22029549
Drug: Atomoxetine 25-100
RxNorm normalized name: atomoxetine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 25-100 mg (mean final dose = 89.9 mg)
Trial: 22029549
Drug: On-treatment drinking
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment drinking levels
Trial: 18284391
Drug: Sodium carboxymethylcellulose
RxNorm normalized name: Carboxymethylcellulose Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium carboxymethylcellulose hydrocolloid polymer treatment
Trial: 11115954
Drug: RTV 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV 200 mg once daily (group A)
Trial: 11115954
Drug: RTV 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV 400 mg once daily (group B)
Trial: 11115954
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg (day 1), 400 mg (day 15), 800 mg (day 18), 1200 mg (day 21)
Trial: 11115954
Drug: Indinavir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 1200 mg/400 mg RTV
Trial: 11115954
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg/400 mg RTV or 1200 mg/200 mg RTV
Trial: 2420106
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH) continuous infusion (400 micrograms bolus followed by 200 micrograms/hour for 6 hours)
Trial: 20889343
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of certainty and high supra-postural task constraint
Trial: 8785030
Drug: Local intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local intra-arterial injection of cisplatin at a dose of 100 mg concomitant with hemodialysis (HD)
Trial: 8785030
Drug: Local intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local intra-arterial injection of cisplatin at doses of 200 or 250 mg concomitant with hemodialysis (HD)
Trial: 8785030
Drug: Local intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local intra-arterial injection of cisplatin (dose not specified) without concomitant hemodialysis (HD)
Trial: 20924975
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (200 mg daily for 6 months)
Trial: 11755589
Drug: Load cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Load cycling (90N for 5000 cycles) with Prompt L-Pop
Trial: 11755589
Drug: Non-load cycling
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-load cycling (control group) with Prompt L-Pop
Trial: 3015041
Drug: COM-ANV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COM-ANV therapy
Trial: 3015041
Drug: ANV-COM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV-COM therapy
Trial: 3015041
Drug: ANV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV therapy
Trial: 27347788
Drug: TRANSITECH (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRANSITECH (2 tablets daily for 10 days)
Trial: 18922425
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion (0.2 microg/kg/min) for 24 hours
Trial: 15618526
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment group
Trial: 9590840
Drug: 1% miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% miconazole suspension
Trial: 1747568
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND; 50 mg IM every three weeks)
Trial: 1747568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group 1 (CST therapy for less years)
Trial: 28089425
Drug: Laryngeal Mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laryngeal Mask Airway I‐Gel
Trial: 24063835
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol); n = 700
Trial: 24063835
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel); n = 699
Trial: 19691668
Drug: Viusid (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viusid (three sachets daily) with hypocaloric diet and aerobic exercise
Trial: 28138980
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of canagliflozin
Trial: 28138980
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing of canagliflozin
Trial: 28138980
Drug: Canagliflozin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (both dosing regimens)
Trial: 21736448
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of erythropoietin (EPO) for 4 months
Trial: 21736448
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of erythropoietin (EPO) for 4 months
Trial: 18443671
Drug: CR tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR tramadol (150 mg daily, titrated to a maximum of 400 mg once daily)
Trial: 10638884
Drug: Maximal bilevel
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal bilevel training (45 minutes daily, 5 days a week for 6 weeks, working 2.03+/‐0.4 kJ/kg per session)
Trial: 10638884
Drug: O2 cart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O2 cart pushers (45 minutes daily, 5 days a week for 6 weeks, working 1.44+/‐.35 kJ/kg per session)
Trial: 9338536
Drug: Prophylactic inhaled
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic inhaled steroids
Trial: 1524961
Drug: Plain prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain prednisolone tablets (30 mg)
Trial: 1524961
Drug: Enteric-coated prednisolone
RxNorm normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated prednisolone tablets (30 mg)
Trial: 1524961
Drug: Plain and
RxNorm normalized name: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain and enteric-coated prednisolone tablets (30 mg)
Trial: 3156329
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous injection of fibronectin (1 mg/kg)
Trial: 3156329
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of one-half of the dose followed by continuous infusion of the remaining half-dose over a 6-hour period (group B + P)
Trial: 27159166
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) immunization with CN54 gp140 at 20 or 100 μg co-administered with Glucopyranosyl Lipid Adjuvant (GLA)
Trial: 27159166
Drug: Intranasal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (IN) immunization with CN54 gp140 and 0.5% chitosan
Trial: 27159166
Drug: Intravaginal (IVAG)
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal (IVAG) immunization with CN54 gp140 in an aqueous gel
Trial: 27159166
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) boosting after IN priming
Trial: 24107072
Drug: GSK2336805 (monotherapy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2336805 (monotherapy)
Trial: 22784346
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Mahatma Gandhi Mission Hospital treatment)
Trial: 20833796
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcohol (target BAC = .10%)
Trial: 16164447
Drug: salbutamol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol (5 mg/mL)
Trial: 12753877
Drug: Tramadol/acetaminophen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/acetaminophen combination tablets (37.5 mg tramadol/325 mg acetaminophen)
Trial: 23441841
Drug: Berberine 500
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 500 mg twice a day for 3 months
Trial: 19375278
Drug: Exercise-only control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-only control treatment
Trial: 11495220
Drug: Low-fat, high-fiber,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-fiber, high-fruit/vegetable diet (20% of energy from fat, 18 g/1,000 kcal/day fiber, 3.5 servings/1,000 kcal/day fruit/vegetable)
Trial: 7812890
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% eye drops, administered twice daily for 4 weeks
Trial: 3235806
Drug: Sterile technique
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile technique for preparation of the skin over the vascular access site
Trial: 3235806
Drug: Clean technique
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean technique for preparation of the skin over the vascular access site
Trial: 8400973
Drug: Metoprolol 50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50‐100 mg twice daily
Trial: 8400973
Drug: Isradipine 2.5‐5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5‐5.0 mg twice daily
Trial: 8400973
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blockers
Trial: 29094444
Drug: Metformin (MTF)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MTF) 1700 mg/day
Trial: 26847305
Drug: Ultrasound-guided steroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided steroid injection into scalene muscles
Trial: 22508732
Drug: Epidural steroids
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroids
Trial: 16848109
Drug: Pasteurized cow
RxNorm normalized name: Pasteurized cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasteurized cow milk yogurt (15 ml/kg/day) plus routine hospital treatment
Trial: 16848109
Drug: Routine hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hospital treatment
Trial: 14685931
Drug: No treatment/conversation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment/conversation only
Trial: 10973843
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine, with possible addition of enalapril, hydrochlorothiazide, or both)
Trial: 8451663
Drug: Two-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component acellular pertussis vaccine (LPF/FHA)
Trial: 8451663
Drug: Standard whole-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard whole-cell pertussis vaccine
Trial: 2434108
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered human pepsinated immunoglobulin G (HPIG, Gamma‐Venin)
Trial: 2434108
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified what treatment or intervention was used)
Trial: 30259623
Drug: Exenatide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2.5 mcg
Trial: 23462720
Drug: Intraperitoneal (IP)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) chemotherapy with cisplatin and paclitaxel
Trial: 23462720
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) chemotherapy with paclitaxel and cisplatin
Trial: 21289328
Drug: Tolvaptan (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (in patients with serum sodium concentration of <130 meq/L)
Trial: 21289328
Drug: More severely
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More severely hyponatremic patients (serum sodium concentration of <135 meq/L) receiving placebo
Trial: 19260800
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg administered 1 hour before SWL and 24 hours later
Trial: 19260800
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pretreatment medications)
Trial: 11502641
Drug: O(2) administration
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O(2) administration
Trial: 8303624
Drug: MK-0679 (825
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0679 (825 mg, orally)
Trial: 3706879
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate (AS) 6.4 mg total (3.2 mg inhaled twice)
Trial: 3706879
Drug: Metaproterenol sulfate
RxNorm normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaproterenol sulfate (MP) 30 mg total (15 mg inhaled twice)
Trial: 30928806
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m2, intravenously, on day 1 and day 8)
Trial: 30928806
Drug: Vinorelbine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (25 mg/m2, intravenously, on day 1, day 8 and day 15)
Trial: 22084195
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 150 × 10(6) autologous bone marrow mononuclear cells (BMCs)
Trial: 22084195
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 150 × 10(6) autologous BMCs
Trial: 19407945
Drug: Intravenous dripping
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dripping of Qingkailing Injection in combination with oral intake of Er'tong Qingfei Oral Liquid
Trial: 19407945
Drug: Intravenous dripping
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dripping of ribavirin injection in combination with oral intake of potassium guaiacol sulfonate oral liquid